Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients
Saeki, T.; Jinushi, K.; Kim, R.; Toi, M.; Saeki, K.; Yoshinaka, K.; Yanagawa, E.; Niimoto, M.; Hattori, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Part 1): 827-831
1989
ISSN/ISBN: 0385-0684 PMID: 2712579 Document Number: 342968
Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer. The protocol of this therapy was as follows: On day 1, 500 mg/body cyclophosphamide (CPM) was administered by drip infusion, and on day 2, 200 mg/m2 methotrexate (MTX) was infused intravenously for 30 min; immediately after, 500 mg/body 5-fluorouracil (5-FU) was injected by bolus infusion for 5-10 min. On day 3, 24 hours after MTX administration, leucovorin rescue was added. This combination chemotherapy was repeated every two weeks. As a result, 35 of 52 patients were evaluable and the response rate (CR + PR) was investigated; 2/21 (9.5%) for gastric, 2/7 (28.6%) for breast, and 0% for miscellaneous. As complications for side effect, general fatigue, anorexia, nausea, vomiting and stomatitis were observed symptomatically, and leukopenia and thrombocytopenia were recognized in laboratory data as dose limiting factors.